<DOC>
	<DOC>NCT00111085</DOC>
	<brief_summary>The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.</brief_summary>
	<brief_title>Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Vasospasm, Intracranial</mesh_term>
	<criteria>Female patients aged 18 to 70 years (inclusive) or male patients aged 45 to 70 (inclusive) or males aged 18 to 44 (inclusive) who are surgically or naturally sterile or can personally sign the core Informed Consent Patients with a ruptured saccular aneurysm that has been confirmed by digital subtraction angiography (DSA) and for which clipping or coiling (endovascular obliteration) is possible. Patients with a diffuse or localized thick subarachnoid clot on baseline CT scan. Start of screening within 48 hours post onset of aSAH clinical symptoms. WFNS Grades IIV, and those Grade V patients who improve to Grade IV or less after ventriculostomy. Patients with SAH due to other causes (e.g., trauma or rupture of fusiform or mycotic aneurysms) Patients with intraventricular or intracerebral blood, in the absence of subarachnoid blood. No visualized clot or presence of only localized thin clot on CT Presence of any degree of cerebral vasospasm on screening angiogram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>aneurysmal subarachnoid hemorrhage (aSAH)</keyword>
	<keyword>vasospasm</keyword>
	<keyword>delayed ischemic neurological deficits (DIND)</keyword>
	<keyword>computer tomography scan (CT scan)</keyword>
	<keyword>digital subtraction angiography (DSA)</keyword>
	<keyword>endothelin A receptor</keyword>
	<keyword>clazosentan</keyword>
</DOC>